Correction to “Real‐World Outcomes of Pembrolizumab Monotherapy in Metastatic Non‐Small Cell Lung Cancer by Age and Sex: A National Population‐Based Study in Australia”

Documenti analoghi

• Real‐World Outcomes of Pembrolizumab Monotherapy in Metastatic Non‐Small Cell Lung Cancer by Age and Sex: A National Population‐Based Study in Australia
  di: Chin Hang Yiu, et al.
  Pubblicazione: (2026)
• Comparative Effectiveness of First‐Line Pembrolizumab vs. Chemotherapy in aNSCLC : A Norwegian Population‐Based Cohort Study
  di: Simon Boge Brant, et al.
  Pubblicazione: (2025)
• Quantification of Age and Sex Ratio Differences between Trial and Target Population for New Drugs
  di: Miquel Serra‐Burriel, et al.
  Pubblicazione: (2026)
• Predictive Modeling of Drug‐Related Adverse Events with Real‐World Data: A Case Study of Linezolid Hematologic Outcomes
  di: Anu Patel, et al.
  Pubblicazione: (2024)
• Disentangling Anti‐Tumor Response of Immunotherapy Combinations: A Physiologically Based Framework for V937 Oncolytic Virus and Pembrolizumab
  di: Aymara Sancho‐Araiz, et al.
  Pubblicazione: (2024)